### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
DMB Number:	3235-0287				
Estimated average burden nours per response 0.5					
ours per response					

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)													
Name and Address of Reporting Person * Schutz James J				2. Issuer Name and Ticker or Trading Symbol Sonoma Pharmaceuticals, Inc. [SNOA]						:	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner				
(Last) (First) (Middle) C/O SONOMA PHARMACEUTICALS, INC., 1129 N. MCDOWELL BLVD.				3. Date of Earliest Transaction (Month/Day/Year) 01/02/2018						X Officer (give title below) Other (specify below)  Chief Executive Officer					
(Street) PETALUMA, CA 94954			4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line)  X_Form filed by One Reporting Person  Form filed by More than One Reporting Person					
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqui						Acqui	ired, Disposed of, or Beneficially Owned				
(Instr. 3)		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr. 8)	ction	(A) or Disposed of (D) (Instr. 3, 4 and 5)		of	ired 5. Amount of Securities Beneficially Owned Fol Reported Transaction(s) (Instr. 3 and 4)		Following	Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership	
						Code	V Amount (A) or (D)		Price				or Indirect (I) (Instr. 4)	(Instr. 4)	
Common value per	Stock, \$0. share	0001 par	01/02/2018			A		17,21	1 A	<u>(1)</u>	33,385			D	
Reminder: 1 indirectly.	Report on a	separate line fo		erivative Secu	uritie	es Acquire	Persecontains the feet	ons whained in orm dis	n this for splays a of, or Ben	m are curre eficial	not req	uired to re	nformation espond unl ntrol numb	ess	C 1474 (9- 02)
Security	Conversion	3. Transaction Date (Month/Day/Y	n 3A. Deemed Execution Dany	4. Transaction Code (Instr. 8)		5. Number of	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction((Instr. 4)	Ownersh Form of Derivativ Security: Direct (I or Indire	·	
				Code	V	(A) (D)	Date Exer	cisable	Expiration Date	n Title	Amount or Number of Shares				
Repor	ting O	wners													

Danastina Orman Nama / Addusas	Relationships						
Reporting Owner Name / Address		10% Owner	Officer	Other			
Schutz James J C/O SONOMA PHARMACEUTICALS, INC. 1129 N. MCDOWELL BLVD. PETALUMA, CA 94954	X		Chief Executive Officer				

# **Signatures**

/s/ Jim Schutz	01/03/2018
**Signature of Reporting Person	Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The stock was granted by the Issuer as a bonus for services and vests immediately.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

